James J. Gibbons - Concepedia

Author

James J. Gibbons

Pearl River Community College

Also Known As

JAMES GIBBONS, JAMES J. GIBBONS, JAMES J. GIBBONS, James Gibbons, James J Gibbons, James J. Gibbons, James J. Gibbons

134

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Pearl River Community College Drury University Saint Louis University NOAA Chemical Sciences Laboratory University of Missouri–St. Louis

About

James J. Gibbons is an author at Pearl River Community College specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	1.9K
2	Engineering	11	13	321
3	Natural Sciences	10	10	832
4	Health Sciences	1	1	103
5	Allergy	1	1	12

James J. Gibbons

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Mehran S. Neshat, Ingo K. Mellinghoff, Chris Tran, Proceedings of the National Academy of Sciences	2001	973
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Jennifer M. Golas, Kim Arndt, Carlo Etienne, PubMed K562 XenograftsMixed-phenotype Acute LeukemiaApoptosisCell DeathTumor Biology	2003	414
Biochemical, Cellular, and <i>In vivo</i> Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin Ker Yu, Lourdes Toral‐Barza, Celine Shi, Cancer Research Chemoprevention StrategyCellular PharmacologySelective InhibitorsMtor SelectivityChemical Biology	2009	326
Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound <b>26</b> (PKI-587), a Highly Efficacious Dual Inhibitor Aranapakam M. Venkatesan, Christoph M. Dehnhardt, Efren Delos Santos, Journal of Medicinal Chemistry	2010	210
Synthesis and SAR of [1,2,4]Triazolo[1,5-<i>a</i>]pyrimidines, a Class of Anticancer Agents with a Unique Mechanism of Tubulin Inhibition Nan Zhang, Semiramis Ayral‐Kaloustian, Thai Nguyen, Journal of Medicinal Chemistry Combinatorial ChemistryBioorganic ChemistryOrganic ChemistryPharmacotherapyAnticancer Agents	2006	209
Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2 Ker Yu, Celine Shi, Lourdes Toral‐Barza, Cancer Research Antitumor ActivityChemoprevention StrategyPharmacotherapyCancer BiologyTumor Biology	2010	208
Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, Clinical Cancer Research	2018	188
A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis Boris Shor, Weiguo Zhang, Lourdes Toral‐Barza, Cancer Research Chemoprevention StrategyGlobal Protein SynthesisCancer BiologyTumor BiologyProtein Synthesis	2008	120
RSD Score James J. Gibbons, Peter R. Wilson Clinical Journal of Pain Pain SyndromeHealth SciencesPain MedicineChronic Musculoskeletal ConditionDiagnosis	1992	103
ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines Arie Zask, Jeroen C. Verheijen, Kevin J. Curran, Journal of Medicinal Chemistry Chemical BiologyPharmaceutical ChemistryTumor BiologyMedicinal ChemistryMammalian Target	2009	98

Page 1